600998 Jointown Pharmaceutical Group
- 5.25
- +0.10+1.94%
Jointown Pharmaceutical Group News
jointown pharmaceutical group (600998): reits has been accepted, driving value reassessment.
Investment Highlights: On September 25, 2024, Jointown Pharmaceutical Group (九州通) announced that the Huatai Jointown Pharmaceutical Warehousing and Logistics Closed-End Infrastructure Securities Investment Fund (hereinafter referred to as public fund REITs) obtained the approval on September 24.
Jointown Pharmaceutical Group (600998): The public offering REITS issuance application materials have been formally submitted to the China Securities Regulatory Commission and the Shanghai Stock Exchange, continuously advancing the real estate securitizat
Officially submitted the public offering REITs issuance application materials to the China Securities Regulatory Commission and the Shanghai Stock Exchange. The project is progressing smoothly. On September 22, the company announced that the progress of the public offering REITs issuance for medical warehousing and logistics infrastructure is proceeding smoothly.
Express News | Jointown Pharmaceutical Group: Has officially submitted the public REITs application materials for medical and pharmaceutical warehousing logistics infrastructure to the China Securities Regulatory Commission and the Shanghai Stock Exchange.
Express News | Jointown Pharmaceutical Group has established a new company, with business including AI industry application system integration services
jointown pharmaceutical group (600998.SH): to privately issue preferred shares for listing transfer.
Jointown Pharmaceutical Group (600998.SH) announced on September 18th that, with the approval of the Shanghai Stock Exchange, the preferred shares issued by the company will be listed and traded on the Shanghai Stock Exchange's integrated business platform starting from September 24th, 2024.
Express News | Jointown Pharmaceutical Group: The issuance of 0.179 billion preferred shares to specific entities has obtained registration approval.
Express News | The latest list of China's top 500 enterprises has been released, with 14 Hubei companies making the list.
China Approves Jointown Unit's Active Pharmaceutical Ingredient Application for Edema Drug; Shares Fall 3%
Express News | Jointown Pharmaceutical Group and others establish a new company including the business of second-hand car brokerage.
Express News | Jointown Pharmaceutical Group: Subsidiary Fursultiamine Active Pharmaceutical Ingredient Obtains Market Approval.
A subsidiary has been "blacklisted" by Shenzhen for one year. Jointown Pharmaceutical Group claims to be "in the process of defending". The industry believes that the intensity of procurement supervision is continuously increasing.
Recently, Jointown Pharmaceutical Group's subsidiary, Jointown Medical Device, was fined and banned from participating in Shenzhen procurement for one year due to providing false information in a tender at a hospital in Shenzhen. Jointown Pharmaceutical Group responded to a reporter from Caijing.com.cn, stating that this incident is a pending matter, and they have organized appeal materials and are currently undergoing administrative reconsideration. This year, several listed companies have been fined for violations in the bidding and procurement process, leading industry insiders to suggest that companies should pay more attention to compliance with details during the bidding process.
Ping An Health and Jointown Health Technology have reached a strategic cooperation, bringing together new productive forces of medical and health technology.
Recently, Ping An Health Medical Technology Co., Ltd. (stock abbreviation "Ping An Good Doctor", 1833.HK, hereinafter referred to as "Ping An Health") and Jointown Pharmaceutical Group (hereinafter referred to as "Jointown Pharmaceutical Group") officially announced the establishment of a strategic partnership. Wu Jun, President of Ping An Health, Zheng Bosong, Senior Vice President of Ping An Health, and Liu Jinghan, CEO of Jointown Pharmaceutical Group, attended the event. This cooperation not only represents the strong alliance of the two parties in the field of medical and health, but also an innovative development and in-depth exploration of the new model of "Internet + medical + pharmaceutical", aiming to provide more convenient and high-quality services to users.
Jointown Pharmaceutical Group (600998.SH): In August, the company did not repurchase stocks through centralized bidding trading.
On September 2, JIuzhou Tong (600998.SH) announced that in August 2024, the company did not repurchase stocks through centralized auction trading. As of August 30, 2024, the company has repurchased a total of 54.0805 million shares, accounting for 1.07% of the total share capital, with the highest purchase price at 5.18 yuan/share and the lowest price at 4.42 yuan/share. The total amount paid is 258.8364 million yuan (excluding commission and fees). The progress of the company's repurchase complies with relevant laws, regulations, and the company's repurchase plan.
jointown pharmaceutical group (600998.SH) repurchased 1.07% of its shares, spending 0.259 billion yuan.
Jointown Pharmaceutical Group (600998.SH) announced that the company has repurchased a total of 54.0805 million shares, accounting for 1% of the total share capital....
"Three new two transformations" have achieved results, and the performance of Jointown Pharmaceutical Group has been improving quarter by quarter.
Facing the changes in the market environment, jointown pharmaceutical group, a leading private pharmaceutical distribution company, has unlocked some new development secrets. On the evening of August 26th, the company released its semi-annual report for 2024. During the reporting period, the company achieved revenue of 77.171 billion yuan, net income attributable to parent company of 1.208 billion yuan, and non-recurring net income attributable to parent company of 1.18 billion yuan in the first half of the year. Among them, the company's performance in the second quarter was significantly better than in the first quarter. The second quarter realized a net income of 0.67 billion yuan, a quarter-on-quarter increase of 24.6%; the net cash flow from operating activities was 0.453 billion yuan, which has improved compared to the first quarter, and it is expected that the net cash flow from operating activities for the whole year will be "}
Jointown Pharmaceutical Group (600998): Empowering the "Three New Two Transformations" Strategy for Rapid Development of Innovative Business.
Event: On August 27, 2024, Jointown Pharmaceutical Group released its 2024 interim report. In the first half of 2024, the company achieved revenue of 77.171 billion yuan (-2.76%), and net income attributable to shareholders was 1.208 billion yuan (-10.08%).
Jointown Pharmaceutical Group (600998): Performance meets expectations, new business shows good development trend.
1H24 performance meets our expectations. The company announced 1H24 performance: revenue of 77.171 billion yuan (YoY-2.76%); net income attributable to the parent company of 1.208 billion yuan (YoY-10.08%), corresponding to earnings per share of 0.
Jointown Pharmaceutical Group's H1 Attributable Profit Slides 10%
Kyushu-dori 2024 Semi-Annual Report
Kyushu-dori 2024 Semi-Annual Report Summary
Analysis
Price Target
No Data
No Data